1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Medicenna Therapeutics Corp.
  6. News
  7. Summary
    MDNA   CA58490H1073

MEDICENNA THERAPEUTICS CORP.

(MDNA)
  Report
Delayed Toronto Stock Exchange  -  05/16 03:58:59 pm EDT
1.360 CAD   -4.90%
05/11Medicenna Presents Phase 1/2 ABILITY Data Highlighting MDNA11's "Favorable" Clinical Profile at Cancer Immunotherapy Meet
MT
05/11Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting
CI
05/11Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medicenna Therapeutics up 12.7% in US Trade, Details Management Change, Appoints Development Advisory Committee

01/18/2022 | 07:07am EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. 0.19% 243.87 Delayed Quote.8.40%
MEDICENNA THERAPEUTICS CORP. -4.90% 1.36 Delayed Quote.-35.24%
NOVARTIS AG 0.16% 87.64 Delayed Quote.9.03%
ON SEMICONDUCTOR CORPORATION -1.83% 55.15 Delayed Quote.-18.80%
All news about MEDICENNA THERAPEUTICS CORP.
05/11Medicenna Presents Phase 1/2 ABILITY Data Highlighting MDNA11's "Favorable" Clinical Pr..
MT
05/11Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11'..
CI
05/11Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinica..
AQ
05/02Medicenna up 7.3% in US Pre-Market as Details Promising New Clinical Data From Phase 1/..
MT
05/02MEDICENNA THERAPEUTICS : Announces New Clinical Data Showing Dose-Dependent Stimulation of..
PU
05/02Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer..
AQ
05/02Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimula..
CI
04/27MEDICENNA THERAPEUTICS : to Present at the 2022 Bloom Burton & Co. Healthcare Investor Con..
PU
04/27Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Co..
AQ
04/08Medicenna Presents Preclinical Data Showing Anti-Cancer Activity at the AACR Annual Mee..
MT
More news
Analyst Recommendations on MEDICENNA THERAPEUTICS CORP.
More recommendations
Financials
Sales 2022 - - -
Net income 2022 -25,1 M -19,5 M -19,5 M
Net Debt 2022 - - -
P/E ratio 2022 -2,92x
Yield 2022 -
Capitalization 75,6 M 58,5 M 58,5 M
Capi. / Sales 2022 -
Capi. / Sales 2023 52,6x
Nbr of Employees 13
Free-Float 66,9%
Chart MEDICENNA THERAPEUTICS CORP.
Duration : Period :
Medicenna Therapeutics Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDICENNA THERAPEUTICS CORP.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,36 CAD
Average target price 11,48 CAD
Spread / Average Target 744%
EPS Revisions
Managers and Directors
Fahar Merchant Chairman, President & Chief Executive Officer
Elizabeth Williams Chief Financial Officer & Secretary
Martin Bexon Chief Medical Officer
Albert George Beraldo Independent Non-Executive Director
Chandrakant J. Panchal Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDICENNA THERAPEUTICS CORP.-35.24%61
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153